# Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

> **NCT00471133** · PHASE1 · COMPLETED · sponsor: **Ichor Medical Systems Incorporated** · enrollment: 24 (actual)

## Conditions studied

- Melanoma (Skin)
- Intraocular Melanoma

## Interventions

- **BIOLOGICAL:** Xenogeneic Tyrosinase DNA Vaccine
- **DEVICE:** TriGrid Delivery System for Intramuscular Electroporation

## Key facts

- **NCT ID:** NCT00471133
- **Lead sponsor:** Ichor Medical Systems Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471133, "Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00471133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*